Callan Family Office LLC Raises Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Callan Family Office LLC increased its stake in Alnylam Pharmaceuticals by 187.9% in Q2, bringing their total holdings to 2,931 shares valued at approximately $956,000.
• Insider transactions showed CEO Yvonne Greenstreet sold 8,924 shares for about $4 million, resulting in a 12.01% decrease in her ownership position.
• Alnylam Pharmaceuticals recently reported a quarterly revenue increase of 17.3% year-over-year, with earnings per share beating analysts' expectations by $0.86.

Callan Family Office LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 187.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,931 shares of the biopharmaceutical company's stock after purchasing an additional 1,913 shares during the period. Callan Family Office LLC's holdings in Alnylam Pharmaceuticals were worth $956,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in ALNY. Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth $243,000. GAMMA Investing LLC raised its stake in shares of Alnylam Pharmaceuticals by 14.3% during the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock worth $166,000 after buying an additional 77 shares during the last quarter. NorthCrest Asset Manangement LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth $323,000. Wealth Enhancement Advisory Services LLC raised its stake in shares of Alnylam Pharmaceuticals by 14.6% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 14,404 shares of the biopharmaceutical company's stock worth $3,889,000 after buying an additional 1,838 shares during the last quarter. Finally, QRG Capital Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 97.9% during the 1st quarter. QRG Capital Management Inc. now owns 1,949 shares of the biopharmaceutical company's stock worth $526,000 after buying an additional 964 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 8,924 shares of the company's stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the completion of the transaction, the chief executive officer owned 65,409 shares of the company's stock, valued at $29,568,138.45. This represents a 12.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Dennis A. Ausiello sold 31,448 shares of the company's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the transaction, the director directly owned 911 shares of the company's stock, valued at approximately $397,724.38. This represents a 97.18% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 98,144 shares of company stock worth $44,160,261. Corporate insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Trading Up 0.6%

Shares of ALNY stock opened at $459.66 on Monday. The firm has a 50-day moving average price of $451.37 and a 200 day moving average price of $346.13. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $484.21. The company has a market capitalization of $60.25 billion, a price-to-earnings ratio of -186.10 and a beta of 0.36. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. During the same quarter in the prior year, the company posted ($0.13) EPS. The company's quarterly revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ALNY shares. Raymond James Financial started coverage on Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They set an "outperform" rating and a $370.00 price target for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 8th. Citigroup lifted their price target on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a "buy" rating in a research note on Tuesday, September 2nd. Jefferies Financial Group lifted their price target on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a research note on Monday, July 7th. Finally, Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Twenty-four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $457.16.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.